Percutaneous Coronary Intervention Outcomes in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus and Systemic sclerosis by Mohamed, MO et al.
For Peer Review
Percutaneous Coronary Intervention Outcomes in Patients 




Manuscript Type: Original Article
Date Submitted by the 
Author: 20-Nov-2019
Complete List of Authors: Martinez, Sara; Providence St. Peter Hospital, Cardiology
Mohamed, Mohamed; Keele University, Cardiology
Potts, Jessica; Keele University, Cardiology
Abhishek, Abhishek; City Hospital, Academic Rheumatology
Roddy, Edward; Keele University, School of Primary, Community and 
Social Care
Savage, Michael; Thomas Jefferson University, Cardiology
Bharadwaj, Aditya; Loma Linda University Medical Center, Cardiology
Kwok, Chun Shing; Keele University, Cardiology
Bagur, Rodrigo; Keele University, Cardiology
Mamas, Mamas; Keele University, Cardiology
Keywords<br>Please select a 
minimum FIVE keywords from 
the list provided. These 
keywords will be used to 
select reviewers for this 
manuscript.  The keywords in 
the main text of your paper 
do not need to match these 
words.:
Rheumatoid arthritis < RHEUMATIC DISEASES, Scleroderma and related 
disorders < RHEUMATIC DISEASES, Cardiovascular < TISSUES, 






Percutaneous Coronary Intervention Outcomes in Patients with Rheumatoid Arthritis, 
Systemic Lupus Erythematosus and Systemic sclerosis
Short Title: PCI outcomes in rheumatic disease.
Sara C. Martinez*1, Mohamed Mohamed2,3, Jessica Potts2, Abhishek Abhishek4, Edward 
Roddy5, Michael Savage6, Aditya Bharadwaj 7,8, Chun Shing Kwok2,3, Rodrigo Bagur1, Mamas 
A. Mamas2,3
 
(1) Division of Cardiology, Providence St. Peter Hospital, Olympia, Washington, USA
(2) Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele 
University, UK 
(3) Royal Stoke University Hospital, Stoke-on-Trent, UK
(4) Academic Rheumatology, University of Nottingham, Nottingham, UK
(5) School of Primary, Community and Social Care, Keele University, UK
(6) Haywood Academic Rheumatology Centre, Midland Partnership NHS Foundation 
Trust, Haywood Hospital, Burslem, UK.
(7) Department of Medicine (Cardiology), Thomas Jefferson University Hospital, 
Philadelphia, Pennsylvania, United States
(8) Cardiology, Loma Linda University, California, United States
*These authors contributed equally – joint first authors
Correspondence to:
Prof. Mamas A. Mamas
Professor of Cardiology
Keele Cardiovascular Research Group, 
Centre for Prognosis Research, 
Institute for Primary Care and Health Sciences, 
Keele University, UK
mamasmamas1@yahoo.co.uk
Word count (inc. title page, abstract and references):  5200
































































Objective: Patients with autoimmune rheumatic disease (AIRD) are at an increased risk of 
coronary artery disease. The present study sought to examine the prevalence and outcomes of 
AIRD patients undergoing percutaneous coronary intervention (PCI) from a national 
perspective.  
Methods: All PCI-related hospitalizations recorded in the United States (US) National 
Inpatient Sample (2004 to 2014) were included, stratified in to 4 groups: No AIRD, 
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSC). 
We examined the prevalence of AIRD subtypes and assessed their association with in-hospital 
adverse events using multivariable logistic regression (odds ratios (OR) [95% confidence 
interval]). 
Results: Patients with AIRD represented 1.4% (n=90,469) of PCI hospitalizations. The 
prevalence of RA increased from 0.8% (2004) to 1.4% (2014), but other AIRD subtypes 
remained stable. In multivariable analysis, the adjusted odds of in-hospital complications (aOR 
any complication: 1.13 [1.01-1.26]; all-cause mortality:1.32 [1.03-1.71]; bleeding: 1.50 [1.30-
1.74]; stroke: 1.36 [1.14-1.62]) were significantly higher in patients with SSC compared to 
those without AIRD. There was no difference in complications between SLE and RA groups 
and those without AIRD, except higher odds of bleeding in SLE patients (aOR 1.19 [1.09-
1.29]) and reduced odds of all-cause mortality in RA patients (aOR 0.79 [0.70-0.88]).
Conclusion: In a nationwide cohort of US hospitalizations, we demonstrate increased rates of 
all adverse clinical outcomes following PCI in people with SSC, and increased bleeding in 
SLE. Management of such patients should involve a multi-team approach with 
rheumatologists. 
Key Words:  percutaneous coronary intervention, rheumatoid arthritis, systemic sclerosis, 
systemic lupus erythematosus, outcomes.
































































 This is the first study to report prevalence, characteristics and outcomes of AIRD 
patients undergoing PCI. 
 The prevalence of RA increased over 11 years, with no change in SLE and SSC 
undergoing PCI
 PCI outcomes differ according to AIRD subtype, with worse clinical outcomes in 
patients with SSC. 
Introduction
Cardiovascular disease (CVD) remains the leading cause of death for patients in the 
United States, with patients with chronic inflammatory conditions at particular risk of CVD.[1-
4] The most common form of CVD is coronary artery disease (CAD) which is more prevalent 
in patients with autoimmune rheumatic diseases (AIRD) such as rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE) and systemic sclerosis (SSC). This population has a >1.5 
fold increased risk of short-term cardiovascular mortality. [1, 2, 5-7] Several factors place 
patients with AIRD at a heightened risk of coronary artery disease such as accelerated 
atherosclerosis and inflammation, making coronary plaques more vulnerable to rupture and 
subsequent thrombosis.[8] 
Percutaneous coronary intervention (PCI) is the most common modality of 
revascularization in patients with significant CAD. The majority of outcomes data on patients 
with AIRD undergoing PCI are from small studies and case reports.[9-12] Despite 
revascularization in these patients, they will remain at a further risk of future ischemic events 
and disease progression,[13] which is often more aggressive than in patients without AIRD.[7] 
Few studies have examined the outcomes of PCI in patients with common AIRDs such as RA 
and SLE, but they were limited by their small sample sizes or highly selected cohorts from 































































individual centers and, therefore, insufficiently powered to detect any clinically significant 
differences.
The present study sought to examine the prevalence and in-hospital clinical outcomes 
of patients with AIRD undergoing PCI in a national cohort of hospitalizations in the United 
States (US) over an eleven-year period. 
Methods 
Data Source
The study was undertaken in the National Inpatient Sample (NIS) for hospital 
discharges in the United States between 2004 and 2014. The NIS is the largest all–payer 
inpatient health care database in the United States and was developed by the Healthcare Cost 
and Utilization Project (HCUP), which is sponsored by the Agency for Healthcare Research 
and Quality (AHRQ). [14] The NIS dataset contains hospital information on 7 to 8 million 
hospital discharges per year from 2004 onwards. The sampling strategy has changed over time 
in order to produce more generalizable estimates by reducing sampling bias.  Before 2012 the 
NIS retained all discharges, but only from a sample of hospitals. Since the redesign, the NIS 
now samples discharges from all hospitals participating in HUCP, approximating a 20% 
stratified sample of all discharges from US community hospitals. 
Study Design and Population
We identified all individuals who had undergone a PCI between January 2004 and 
December 2014 by identifying all eligible discharges with an International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure code of 00.66 
(Percutaneous Transluminal Coronary Angioplasty), 36.06 (Insertion of non-drug-eluting 
coronary artery stent(s)) or 36.07 (Insertion of a drug-eluting coronary artery stent(s)). Before 
a revision of the codes in 2005 the codes 36.01 (Single vessel percutaneous transluminal 































































coronary angioplasty or coronary atherectomy without mention of thrombolytic agent), 36.02 
(Single vessel percutaneous transluminal coronary angioplasty or coronary atherectomy with 
mention of thrombolytic agent) and 36.05 (Multiple vessel percutaneous transluminal coronary 
angioplasty [PTCA] or coronary atherectomy performed during the same operation, with or 
without mention of thrombolytic agent) were also used and so these codes were also included 
when identifying procedures in discharges from 2004 and 2005. 
All records were eligible for inclusion as long as the discharge record showed that the 
patient had undergone a PCI procedure during their hospital stay and was over the age of 18 
years. Information of patient demographics is recorded for each hospital discharge including 
data regarding age, gender, race, admission type (elective or emergent), admission day 
(weekday or weekend), median household income according to ZIP code and expected primary 
payer. Each discharge record had information on up to 30 diagnoses that the patient had been 
given (15 between 2004 and 2008, 25 between 2009 and 2013 and 30 in 2014), and it was these 
diagnosis codes that were used to identify records with a diagnosis of RA (714.0), SLE (710.0) 
or SSC (710.1). Information was also collected on the long-term use of steroids, V58.65.  All 
records with more than one AIRD were excluded (n=2499, 0.04% of entire cohort), as were 
any records with less than 10% missing data (missing age and primary expected payer, n=9589; 
0.15% of the entire cohort).
 Finally, information about the PCI procedure was determined from the procedure 
codes, including whether the PCI was a multi vessel, single vessel and whether it involved 
bifurcation stenting. The use of adjunctive devices including intracoronary pressure wire, 
intravascular ultrasound and an assist device (such as an intra-aortic balloon pump) were also 
recorded. Where available from the procedure codes we also included the type of stent 
deployed (bare metal, drug-eluting).  
































































In-hospital clinical outcomes and complications were identified. The main outcomes 
chosen included: (a) in-hospital all-cause mortality, (b) and in-hospital complication or (c) a 
composite of any of the in-hospital complications considered. The length of stay and the total 
charge of hospitalization were also considered. The total charge given in the dataset represents 
the amount that hospital billed for the services, but is not representative of the hospital services 
actually cost. Therefore, a charge to cost conversion ratio was used in order to covert the 
reported charges into the actual cost for the payer. 
Procedural complications were also identified using ICD-9-CM codes and patient 
safety indicators including post-operative hemorrhage requiring transfusion, vascular 
complications, cardiac complications including iatrogenic and pericardial complications, 
whether an individual required bail out or emergency coronary artery bypass grafting and post-
operative stroke or transient ischemic attack. Finally, bleeding complications were identified, 
including gastrointestinal, retroperitoneal, intracranial, intracerebral hemorrhage, unspecified 
hemorrhage, and whether a blood transfusion was required. Complications were identified by 
ICD-9-CM codes in any secondary diagnosis field (Supplementary Table S1, available at 
Rheumatology online).
Statistical Analysis
Statistical analysis was performed on Stata/MP version 14.0. Continuous variables are 
presented as median and interquartile range, and categorical data are presented as number and 
percentage. For all analyses, the survey estimation commands were used (by using the svy 
prefix in analyses conducted in Stata), this followed the recommendations from AHRQ for 
analysis of survey data to account for the complex survey design of the NIS database. As 
records were not sampled individually but by hospital number, clustering of records within 































































hospitals was taken into account in the survey estimation. This was done by defining each 
hospital to be the primary sampling unit. For calculation of national estimates and correct 
variances, sampling weights for each individual discharge that were provided by the AHRQ 
were used. The use of sampling weights is required because the design of the study means that 
different observations may have different probabilities of selection. Due to the redesign of the 
NIS data and the alternative sampling strategy used before 2012, these weights needed to be 
updated from the original sampling weights for 2004-2011 in order for the analysis to be 
conducted across all included years.   
Multivariable logistic regression models were fitted using maximum likelihood 
estimation in order to investigate the association of rheumatological diagnoses (RA, SLE, SSC) 
with odds of a) in-hospital death, b) in-hospital PCI complications, including procedure-related 
bleeding, vascular complication, cardiac complication or stroke/TIA, and c) the composite of 
any complication, compared to patients without AIRD, adjusting for potential confounders in 
all models. Confounders included age, gender, ethnicity, median income, primary payer, 
elective admission, day of admission (weekend/weekday) primary diagnosis of MI, any 
diagnosis of STEMI/NSTEMI during admission, diagnosis of shock, hypercholesterolemia, 
patient smoking status, Elixhauser comorbidities, use of an assist device or IABP, use of a bare 
metal or drug eluting stent, bifurcation stenting, fractional flow reserve, single or multi-vessel 
PCI and year of hospitalization, as well as accounting for the clustering of individuals by 
hospital. Confounders measured are presented in Table 1. 
A subgroup analysis was conducted to compare the outcomes of patients with RA with 
and without long-term steroid use.
Results































































A total of 6,558,947 hospitalizations for PCI procedures were recorded in U.S. hospitals 
between 2004 and 2014, of which 90,469 patients (1.4%) had a rheumatological diagnosis. The 
percentages of patients with RA, SLE and SSC were: 1.06 % (n=69,354), 0.27 % (n=17,661) 
and 0.05% (n=3,454), respectively (Table 1). There was an increase in the number of patients 
with RA receiving PCI over the study period (0.8% in 2004 to 1.4% in 2014, p<0.001 for trend) 
(Figure 1), while SLE and SSC remained stable (2004 to 2014: 0.2% to 0.4%, p=0.09, and 
0.1% to 0.1%, p=0.34, respectively).  
Several differences were observed between the study groups. Women comprised the 
majority of PCI cases for RA, SLE, and SSC at 56%, 78%, and 74%, respectively, compared 
to only 33.3% in cases without these conditions. (Table 1) Patients with RA/SLE/SSC were 
more likely to have a primary diagnosis of AMI, more specifically NSTEMI to those without 
any AIRD. Furthermore, patients with RA/SLE/SSC had nearly double the prevalence of 
anemia and hyperthyroidism, as well as a higher prevalence of chronic pulmonary disease. 
(Table 1) The median length of stay was also longer in patients with RA/SLE/SSC compared 
to those without any AIRD (3 vs. 2 days). Furthermore, chronic renal failure was most 
prevalent amongst patients with SLE (17.7%) compared to all other groups (9.6-11.7%). 
However, rates of previous MI (13.2-14.7%) and prior PCI (18.7-19.3%) were similar across 
all groups, and patients with SSC were less likely to have had prior CABG (4.3%) than patients 
without any AIRD (7.4%).
The crude rates of in-hospital all-cause mortality were higher in patients with SLE and 
SSC (1.9% and 2.4%, respectively) compared to patients with RA and those without any AIRD 
(1.6% for both), while all the rheumatological groups (RA/SLE/SSC) were more likely to 
experience any complication, or bleeding, compared to those without AIRD. (Table 2, Figure 
2). The rates of vascular and cardiac complications and stroke were similar between patients 
with and without AIRD.































































In comparison to patients without AIRD, the odds of adverse events were significantly 
higher in patients with SSC in multivariate analysis (any complication: OR 1.13 95% CI 1.01, 
1.26; all-cause mortality: OR 1.32 95% CI 1.03,1.71; bleeding: OR 1.50, 95% CI 1.30, 1.74; 
stroke: OR 1.36 95% CI 1.14, 1.62) and were generally not significant in patients with SLE 
and RA, except reduced odds of all-cause mortality in RA patients (OR 0.79, 95% CI 0.70, 
0.88), and higher odds of bleeding in SLE patients (OR 1.19, 95% CI 1.09, 1.29). (Table 3, 
Figure 3). 
A subgroup analysis was performed to examine the effect of steroid on outcomes in RA 
patients. The RA group was stratified into two subgroups depending on documented chronic 
steroid use (RA-Steroid; n=4518 and RA-no steroid: n=64,836), and the odds of clinical 
outcomes in the RA-steroid group were assessed in comparison to the RA-no steroid group. 
Steroid-treated RA patients comprised less than 0.2% of patients receiving PCI from 2004-
2014, with a much higher use in patients with RA (6.5%) compared to those without AIRD 
(0.4%). Demographic and PCI procedural variables were overall similar between the two 
groups. (Supplementary Table S2, available at Rheumatology online) However, a more severe 
clinical presentation phenotype was present for patients with RA on steroid treatment receiving 
PCI, with a greater percentage of those patients diagnosed with AMI, STEMI, NSTEMI, and 
shock. Patients with RA on steroids were more likely to undergo multivessel PCI compared to 
all other groups. RA patients on steroids had a lower prevalence of diabetes (27.6%), compared 
to RA patients without steroids (31.2%) and those without any AIRD (33.4%). 
There was no difference in the crude rates of all-cause mortality, vascular complications 
and any complication between RA patients with or without chronic steroid use. (Supplementary 
Table S3, available at Rheumatology online) The crude rates of bleeding and cardiac 
complications were higher in the RA-steroid group compared to the RA-no steroid group while 
the rate of stroke was lower in the RA-steroid group. (Supplementary Table S3, available at 































































Rheumatology online) There was no difference in the odds of any complication between both 
RA groups (with and without steroids) and patients without any AIRD or chronic steroid use. 
(Supplementary Table S4, available at Rheumatology online). However, RA patients with long-
term steroid use were associated with reduced odds of all-cause mortality (aOR 0.69 95% CI 
0.52, 0.90), stroke (aOR 0.59 95% CI 0.47, 0.73) and vascular complications (aOR 0.72 95% 
CI 0.52, 0.98) and significantly increased odds of bleeding (aOR 1.35 95% CI 1.18, 1.55) and 
cardiac complications (aOR 1.31 95% CI 1.11, 1.56) compared to patients without AIRD. 
(Supplementary Table S4, available at Rheumatology online, and Figure 3)
Discussion
The present study of more than 90,000 patients with AIRD is by far the largest to report 
in-hospital PCI outcomes in this population. We demonstrate that the prevalence of RA 
amongst patients undergoing PCI has increased over an eleven-year period, while that of other 
rheumatological diagnoses (SLE and SSC) has remained stable. Our analysis demonstrates 
significant differences in the in-hospital clinical outcomes, including any complication, all-
cause mortality, bleeding and stroke after PCI, depending on the subtype of AIRD. Patients 
with SSC were associated with significantly increased odds of all adverse events, compared to 
those without AIRD, whereas patients with SLE were at higher risk of bleeding. We observed 
lower odds of all-cause mortality in patients with RA.
Chronic inflammatory diseases are complex and variable in presentation and 
treatments, with a spectrum of end-organ effects, including those on the cardiovascular system. 
Emerging data are uncovering a growing role for cytokine and immune cell regulation of 
coronary artery and cardiac function, paving the way for future studies in 
“cardioimmunology”.[15] RA, SLE, and SSC augment systemic cytokine signaling of TNF-































































alpha and interleukins 1 and 6, which affect macrophage and monocyte signaling, important 
cell subtypes in atherosclerotic coronary artery disease.[16] A multitude of factors that 
predispose to advanced and more severe presentation of CAD in patients with chronic 
inflammatory diseases including accelerated and more severe atherosclerosis, atypical anginal 
symptoms that lead to delayed presentation, and increased likelihood of plaque rupture or 
thrombosis due to severe lesional inflammation.[8] However, these risk factors are not 
incorporated into traditional cardiovascular risk scores such as the Framingham Risk Score, 
ASCVD Risk Calculator, or Reynolds Score.[17-19] Furthermore, the current evidence on 
outcomes of PCI in patients with AIRD is inconsistent and typically limited to small studies. 
A subgroup analysis of 197 patients with AIRD enrolled in the BASKET-PROVE I (BAsel 
Stent Kosten-Effektivitäts Trial-PROspective Validation Examination) trial reported increased 
hazard ratios (HR) of MACE (HR 1.55 95% CI 1.04, 2.31 ), cardiac death (HR 2.63 95% CI 
1.27, 5.43) and all-cause death (HR 2.05 95% CI 1.14, 3.70) in patients with AIRD, compared 
to those without, over a two year follow-up period.[20] However, this analysis was derived 
from a highly selected cohort of patients enrolled in this trial (only patients requiring stents 
≥3mm and <4mm in diameter, and excluding any patients with planned surgery within 12 
months, those requiring any oral anticoagulation, and those at an increased risk of bleeding) 
making it less generalizable to the wider population. This analysis examined the effect of all-
cause AIRD without stratification of outcomes according to the subtype of disease. 
Furthermore, there is evidence to suggest that patients with AIRD are at a higher risk of 
ischemic disease. In a single-center cohort study of 936 patients with RA, 32 patients (3.4%) 
underwent PCI for significant CAD and experienced a high rate of MACCE (56%) over a mean 
follow-up period of 9 (±7) years, primarily driven by repeat revascularization (47%).[21]
The question of whether RA treatment affects outcomes was evaluated in a single-
center cohort study of lesions of RA patients matched to lesions within control patients. The 































































authors reported that RA predisposes to repeat revascularization at 1 year, with the absence of 
methotrexate and TNF-alpha inhibitors for RA treatment associated with a 50% increased 
relative risk of repeat revascularization following PCI.[13] Patients with AIRD may be less 
likely to be referred for revascularization due to perception of their high risk of adverse 
outcomes, which emphasizes the need for outcomes data in this special population. 
Analyses of nationwide databases provide a real-world vantage of outcomes on 
performed procedures, supplementing controlled trials and prospective cohorts and often 
answering questions on populations excluded from trials or at low prevalence. Yet, even at a 
low prevalence, conclusions from emerging data on large patient samples provides important 
information into clinical outcomes from complex groups of patients, providing insight to 
operators for their decision making processes and assessment of risk. Our present analysis 
demonstrated a rise in the prevalence of RA amongst patients undergoing PCI over 11 years, 
although they still remain a minority of patients (1.4%). Identified RA and other chronic 
inflammatory diseases are also uncommon in other populations and ethnic groups, evidenced 
by a recent study of 171,547 hospitalized patients receiving PCI in Taiwan with a 0.31% and 
0.12% rate of RA and SLE from 2000 to 2010 (RA n = 525, SLE n = 211), respectively.[10] 
In the Taiwanese study, the authors conclude that RA and SLE were independent predictors of 
in-hospital all-cause mortality (OR 1.73 95% CI 1.11, 2.68 and OR 3.81 95% CI 2.02, 7.16, 
respectively), and that RA was associated with an increased hazard of ischemic events (HR 
1.18 95% CI 1.01, 1.39) and a composite MACE endpoint (HR 1.20 95% CI 1.07, 1.34). 
However, this analysis was based on a modest number of patients (<1000).
SSC is characterized by obliterative vasculopathy and tissue fibrosis. Peripheral 
vascular and arterial access is poor in SSC and the vasculature is fibrosed.[22] This may have 
contributed to our finding of increased risk of post-procedure bleeding in this population. We 
observed a higher risk of all-cause mortality and stroke in SSC following PCI. This is a novel 































































finding and has not be reported before.  People with SSS are at an increased risk of stroke and 
this may be further enhanced in a hypercoagulable post-operative period.[23, 24]
We observed higher odds of post-procedural bleeding in people with SLE. This could 
be due to thrombocytopenia and platelet dysfunction which are common manifestations of 
disease activity in SLE.[25] In addition to this, patients with SLE are at increased risk of anti-
phospholipid antibody syndrome and may be prescribed oral anticoagulants. It is possible that 
some patients underwent emergency PCI while they were anticoagulated. Finally, 
hydroxychloroquine, the first line immune suppressive treatment used in people with lupus has 
been shown to have an anti-thrombotic effect and may contribute to increased risk of post-
procedure bleeding.[26]
Our analysis demonstrates differences in mortality and clinical outcomes between 
patients with and without AIRD. We show that patients with SSC are at a higher adjusted risk 
of all-cause mortality and complications (any complication, bleeding and stroke) as compared 
to those without AIRD, which is a significant finding. Although SSC patients have been 
previously shown to be at a higher risk of AMI, no study to date has reported outcomes in this 
population.[27] Furthermore, we observe a similarity in outcomes between patients with RA 
and SLE and those without AIRD, except lower all-cause mortality in patients with RA and 
higher bleeding risk in those with SLE. The latter findings could be explained by differences 
in pharmacological regimens that remain unadjusted for in our analysis or other residual 
confounders. A further possibility to explain the apparent reduced mortality in RA subjects is 
that further ischemic events may occur in the long-term phase, which is beyond the follow-up 
duration in our study. Nevertheless, the differences in clinical outcomes between AIRD in a 
national cohort of PCI hospitalizations provides real-world insight for operators and guides 
their decision-making when managing this high-risk population that has been previously shown 
to receive less optimal reperfusion therapy.[28]































































Chronic steroid use in patients with diverse autoimmune diseases has been associated 
with an increased risk of metabolic syndrome and cardiovascular disease due to its 
enhancement of plaque formation, arterial stiffness, insulin resistance and lipid levels.[29-31] 
Perversely, the suppression of inflammation by steroids may also decrease the risk of 
cardiovascular disease, although there is limited outcomes data to demonstrate this. No study 
has previously compared outcomes between patients with RA depending on their steroid use. 
We report lower all-cause mortality and stroke after PCI in patients with RA on steroid therapy, 
compared to those without AIRD, albeit the expense of higher rates of bleeding and cardiac 
complications. The lower risk of mortality in patients with RA on steroid therapy may reflect 
an element of selection bias, whereby only the most stable “healthy” patients are intervened 
upon, the rest being managed by medical therapy. Our findings emphasize the importance of 
bleeding-ischemic risk assessment in such patients prior to intervention, and the 
implementation of bleeding avoidance strategies to minimize the risk of bleeding in patients 
with chronic steroid use.[32-34] 
Limitations
Our findings need to be interpreted in light of the inherent limitations of large databases. 
Although the NIS database contained variables of interest, additional data (platelet count, 
antiplatelet regimen, severity and degree of systemic involvement of AIRD and use of disease 
modifying drugs such as tumor necrosis factor (TNF) alpha inhibitors, non-steroidal anti-
inflammatory drugs and methotrexate, and duration of steroid use), the exert and severity of 
coronary disease and lesion complexity are not routinely collected and may provide additional 
information to better stratify risk, case complexity, and procedural outcomes. Additionally, 
NIS only captures in-hospital outcomes and it is possible that longer-term data on mortality 
and other adverse events such as reinfarction follow a more unfavorable course in patients with 































































AIRD. Furthermore, despite the considerable granular data relating to the PCI admission (e.g. 
STEMI on presentation vs. during hospitalization) in NIS, full procedural details are not 
recorded, which limits insights into differences in angiographic findings (e.g. target lesion or 
vessel revascularization and stent thrombosis), PCI procedural techniques (e.g. femoral vs. 
radial access), and possibly clinical outcomes. Furthermore, the NIS dataset does not capture 
platelet or hemoglobin counts, which may influence antiplatelet and stent choice. The NIS 
dataset only captures inpatient PCI procedures and, therefore, our analysis provides no insight 
into the prevalence and outcomes of AIRD in PCI procedures undertaken in the outpatient 
setting. Finally, in keeping with all observational registry work, the possibility of unmeasured 
or unrecognized confounders may contribute to the adverse outcomes, although capture of a 
wide range of comorbid conditions in the NIS may help to mitigate this bias. 
Conclusion
 In a national analysis of PCI hospitalizations over an eleven-year period, we 
demonstrate differences in in-hospital outcomes of patients with AIRD according to disease 
subtype, with SSC patients being at the highest risk of mortality and adverse outcomes. Our 
findings provide operators with further insight into the clinical outcomes of this complex risk-
group with an inherently high risk of progressive coronary artery disease, and support a 
multidisciplinary strategy in managing these patients involving rheumatologists. 
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Figures and legends: 
Figure 1: Prevalence of study groups amongst PCI hospitalizations over the study years. 
Footnote: RA: Rheumatoid arthritis; SLE: Systemic lupus erythematosus; SSC: Scleroderma; Trends: p<0.001 
for RA, p=0.09 for SLE and p=0.34 for SSC.   
Figure 2. In-hospital adverse events of study groups
Footnote: AIRD: autoimmune rheumatic disease; RA: Rheumatoid arthritis; SLE: Systemic lupus 
erythematosus; SSC: Scleroderma. 
Figure 3. Adjusted odds ratios (aOR) of adverse outcomes in rheumatological disease 
groups*
Footnote: *Reference group for each outcome is patients without autoimmune rheumatic disease; RA: 
Rheumatoid arthritis; SLE: Systemic lupus erythematosus; SSC: Scleroderma. 































































Figure 1: Prevalence of study groups amongst PCI hospitalizations over the study years. 
Footnote: RA: Rheumatoid arthritis; SLE: Systemic lupus erythematosus; SSC: Scleroderma; Trends: 
p<0.001 for RA, p=0.09 for SLE and p=0.34 for SSC.   
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Caption : Figure 2. In-hospital adverse events of study groups 
Footnote: AIRD: autoimmune rheumatic disease; RA: Rheumatoid arthritis; SLE: Systemic lupus 
erythematosus; SSC: Scleroderma. 
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Figure 3. Adjusted odds ratios (aOR) of adverse outcomes in rheumatological disease groups* 
Footnote: *Reference group for each outcome is patients without autoimmune rheumatic disease; RA: 
Rheumatoid arthritis; SLE: Systemic lupus erythematosus; SSC: Scleroderma. 
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Table 1: Patient demographics and procedural characteristics of study groups







Age, years, median (IQR) 65 (56, 74) 68 (60, 76) 60 (51, 69) 67 (58, 73)
Males 66.7% 44.2% 21.9% 25.7%
White 63.1% 67.8% 56.8% 67.8%
Black 6.3% 5.7% 15.5% 5.8%
Hispanic 5.3% 3.9% 6.4% 3.6%
Asian/Pacific Islander 1.7% 1.1% 1.1% 1.2%
Native American 0.4% 0.4% 0.4% 0.7%
Other 2.9% 2.2% 2.3% 2.6%
Missing Ethnicity 20.1% 18.8% 17.5% 18.3%
Admission types - Elective 27.2% 22.4% 22.2% 24.3%
Admission Day, Weekday 84.0% 82.2% 81.5% 83.5%
Median ZIP income 
1st quartile 26.3% 26.4% 30.5% 23.3%
2nd quartile 26.8% 28.0% 26.2% 24.5%
3rd quartile 26.8% 25.0% 23.3% 24.5%
4th quartile 22.1% 20.6% 20.0% 27.6%
Expected Primary Payer
Medicare 51.2% 65.4% 53.3% 53.3%
Medicaid 5.8% 4.8% 9.4% 4.3%
Private 34.7% 25.9% 32.0% 30.3%
Uninsured 5.0% 2.0% 3.0% 0.7%
No charge 0.5% 0.2% 0.3% 0.1%
Other 2.8% 1.8% 2.0% 1.2%
Procedure Details
Single vessel PCI 72.9% 73.5% 74.3% 75.7%
Multi-vessel PCI 17.9% 17.4% 16.8% 14.4%
Unknown vessel number 9.2% 9.1% 8.9% 9.9%
Bifurcation stenting 1.7% 1.8% 1.5% 2.1%
Use of assist devise or IABP 3.3% 3.3% 3.1% 4.1%
Bare Metal Stent 22.0% 23.5% 23.6% 25.0%
Drug Eluting Stent 73.3% 71.5% 69.7% 70.6%
Unknown Stent Type 7.0% 7.2% 8.2% 6.6%
Both stent types used 2.3% 2.2% 1.5% 2.2%
Fractional flow reserve 0.7% 1.1% 1.2% 1.3%
Intravascular ultrasound 4.9% 5.4% 5.3% 4.9%
Record Characteristics
Primary diagnosis AMI 41.0% 45.6% 43.3% 42.9%
STEMI 22.9% 23.4% 22.2% 21.1%
NSTEMI 22.8% 27.7% 26.4% 27.4%
Diagnosis of Shock 2.8% 2.9% 3.1% 3.3%
Length of stay, days, median 
(IQR)
2 (1, 4) 3 (1, 4) 3 (2, 5) 3 (1, 5)













































































Hypercholesterolemia 13.5% 11.2% 10.8% 8.1%
Smoking 35.5% 35.0% 33.4% 24.9%
AIDS 0.01% 0.01% 0.01% 0%
Alcohol abuse 2.0% 1.2% 1.2% 0.9%
Anemia 8.6% 16.5% 18.7% 19.3%
Congestive heart failure 0.9% 1.4% 1.4% 3.1%
Chronic Pulmonary disease 15.4% 23.6% 21.7% 17.3%
Coagulopathy 2.2% 2.7% 5.3% 2.0%
Depression 5.3% 8.6% 10.1% 7.8%
Diabetes 33.4% 31.0% 26.5% 21.2%
Drug abuse 1.3% 0.1% 1.9% 1.2%
Hypertension 69.7% 72.6% 70.8% 64.0%
Hyperthyroidism 7.8% 13.9% 14.6% 19.2%
Liver disease 0.1% 0.1% 1.5% 2.6%
Lymphoma 0.3% 0.4% 0.5% 0.5%
Fluid & electrolyte disorders 9.3% 12.9% 13.7% 13.7%
Other Neurological disorders 2.95% 3.8% 5.7% 3.5%
Obesity 12.2% 12.1% 11.5% 5.5%
Paralysis 0.7% 0.7% 1.0% 0.1%
Peripheral vascular disorder 10.3% 11.7% 9.8% 13.9%
Psychoses 1.3% 1.5% 2.1% 0.8%
Pulmonary circulation 
disorders
0.2% 0.3% 0.3% 1.9%
Renal Failure 9.6% 10.7% 17.7% 11.7%
Peptic ulcer disease without 
bleeding
0.03% 0.08% 0.03% 0.03%
Valvular disease 0.3% 0.5% 0.7% 0.9%
Weight loss 0.1% 1.3% 1.4% 2.1%
Metastatic cancer 0.3% 0.3% 0.2% 0.1%
Previous MI 13.2% 13.8% 13.8% 14.7%
Previous PCI 18.9% 18.7% 18.5% 19.3%
Previous CABG 7.4% 6.1% 5.4% 4.3%
Previous CVA 3.8% 4.9% 6.3% 4.4%
AIRD: rheumatological diagnosis; RA: Rheumatoid arthritis; SLE: Systemic Lupus Erythematosus; SSC: 
Systemic sclerosis; AMI: acute myocardial infarction; CABG: coronary artery bypass graft; CAD: coronary 
artery disease; CVA: cerebrovascular accident (stroke or transient ischemic attack); IHD: ischemic heart 
disease; IQR: interquartile range; NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous 
coronary intervention; STEMI: ST-Elevation myocardial infarction







































































Any complication 9.0% 11.6% 12.3% 13.6%
Mortality 1.6% 1.6% 1.9% 2.4%
Bleeding 3.3% 5.7% 6.4% 8.1%
Vascular 
complication 1.0% 1.0% 1.4% 1.0%
Cardiac 
complication 3.0% 3.1% 3.1% 2.5%
Stroke 2.9% 3.4% 2.7% 4.4%
AIRD: rheumatological diagnosis; RA: Rheumatoid arthritis; SLE: Systemic Lupus Erythematosus; 
SSC: Systemic sclerosis






























































Table 3: Adjusted odds ratios (OR) of in-hospital adverse outcomes for each disease type* 
RA SLE SSC
OR (95% CI) p-value OR (95% CI)
p-




complication 0.97 (0.93,1.02) 0.216 1.06 (0.99,1.13) 0.067 1.13 (1.01,1.26) 0.036
Mortality 0.79 (0.70,0.88) <0.001 1.02 (0.87,1.19) 0.853 1.32 (1.03,1.71) 0.030
Bleeding 1.06 (0.99,1.14) 0.068 1.19 (1.09,1.29) <0.001 1.50 (1.30,1.74) <0.001
Stroke 0.95 (0.88,1.03) 0.205 0.91 (0.82,1.02) 0.115 1.36 (1.14,1.62) 0.001
*reference is patients without autoimmune rheumatological diagnosis; CI: confidence interval; RA: Rheumatoid 
arthritis; SLE: Systemic Lupus Erythematosus; SSC: Systemic sclerosis






























































Supplementary table S1: ICD-9-CM codes for complications







Blood transfusion V58.2, 99.0x (procedure)
Post-op haemorrhage requiring transfusion 99.0 (procedure)
Vascular complications
Vascular injury
900-904, 998.2, 447, 868.04 (diagnosis)




Pericardial comp 423.0, 423.3 (diagnosis) 47.0 (procedure)
Requiring CABG 36.1x, 36.2, 36.31, 36.32, 36.9x
Stroke/TIA 997.00-997.03, 430 – 437.9


































































RA - No Steroid
(n=64,836)
RA - Steroid 
(n=4,518)
Age, years, median [IQR] 65 (56, 74) 67 (59,76) 69 (62,77)
Gender – Males 66.7% 43.8% 49.2%
White 63.1% 67.2% 75.8%
Black 6.3% 5.8% 4.9%
Hispanic 5.3% 3.9% 4.5%
Asian/Pacific Islander 1.7% 1.2% 1.0%
Native American 0.4% 0.4% 0.2%
Other 2.9% 2.3% 0.9%
Missing Ethnicity 20.1% 19.2% 12.8%
Admission types - Elective 27.2% 22.5% 20.1%
Admission Day, Weekday 84.0% 82.5% 77.4%
Median ZIP income
1st quartile 26.3% 26.4% 26.8%
2nd quartile 26.8% 28.0% 28.6%
3rd quartile 26.8% 25.0% 24.3%
4th quartile 22.1% 20.6% 20.3%
Expected Primary Payer
Medicare 51.2% 65.1% 69.5%
Medicaid 5.8% 4.7% 3.6%
Private 34.7% 26.1% 22.7%
Uninsured 5.0% 1.9% 2.7%
No charge 0.5% 0.1% 0%
Other 2.8% 1.8% 1.6%
Procedure Details
Single vessel PCI 72.9% 73.6% 72.0%
Multi-vessel PCI 17.9% 17.2% 20.1%
Unknown vessel number 9.2% 9.2% 7.9%






























































Bifurcation stenting 1.7% 1.7% 2.8%
Use of assist devise or IABP 3.3% 3.2% 5.0%
Bare Metal Stent 22.0% 23.3% 26.1%
Drug Eluting Stent 73.3% 71.8% 68.1%
Unknown Stent Type 7.0% 7.2% 7.4%
Both stent types used 2.3% 2.3% 1.6%
Fractional flow reserve 0.7% 1.1% 1.6%
Intravascular ultrasound 4.9% 5.2% 7.2%
Record Characteristics
Primary diagnosis AMI 41.0% 45.0% 54.0%
STEMI 22.9% 23.2% 27.2%
NSTEMI 22.8% 27.3% 34.5%
Diagnosis of Shock 2.8% 2.8% 4.0%
Length of stay, days, median (IQR) 2 (1, 4) 2 (1,4) 3 (2,5)











Hypercholesterolemia 13.5% 11.4% 7.6%
Smoking 35.5% 34.6% 41.3%
AIDS 0.01% 0.003% 0%
Alcohol abuse 2.0% 1.2% 1.8%
Anemia 8.6% 16.3% 18.5%
Congestive heart failure 0.9% 1.4% 1.3%
Chronic Pulmonary disease 15.4% 23.4% 26.6%
Coagulopathy 2.2% 2.7% 2.7%
Depression 5.3% 8.6% 7.4%
Diabetes 33.4% 31.2% 27.6%
Drug abuse 1.3% 1.0% 1.0%
Hypertension 69.7% 72.7% 70.7%
Hyperthyroidism 7.8% 14.0% 13.4%






























































Liver disease 0.1% 0.9% 0.9%
Lymphoma 0.3% 0.4% 0.3%
Fluid & electrolyte disorders 9.3% 12.6% 16.6%
Other Neurological disorders 2.95% 3.8% 3.1%
Obesity 12.2% 12.1% 11.6%
Paralysis 0.7% 0.7% 0.2%
Peripheral vascular disorder 10.3% 11.7% 11.9%
Psychoses 1.3% 1.6% 0.7%
Pulmonary circulation disorders 0.2% 0.3% 0.6%
Renal Failure 9.6% 10.6% 12.0%
Peptic ulcer disease excluding bleeding 0.03% 0.01% 0%
Valvular disease 0.3% 0.5% 0.1%
Weight loss 0.1% 1.3% 1.3%
Metastatic cancer 0.3% 0.03% 0.03%
Previous MI 13.2% 13.8% 14.1%
Previous PCI 18.9% 18.5% 21.7%
Previous CABG 7.4% 6.2% 5.2%
Previous CVA 3.8% 4.8% 6.7%
AIRD: rheumatological diagnosis; RA: Rheumatoid arthritis; SLE: Systemic Lupus Erythematosus; 
SSC: Systemic sclerosis; AMI: acute myocardial infarction; CABG: coronary artery bypass graft; 
CAD: coronary artery disease; CVA: cerebrovascular accident (stroke or transient ischemic attack); 
IHD: ischemic heart disease; IQR: interquartile range; NSTEMI: non-ST-elevation myocardial 
infarction; PCI: percutaneous coronary intervention; STEMI: ST-Elevation myocardial infarction





RA - No Steroid
(n=64,836)
RA - Steroid 
(n=4,518) p-value
Any complication 9.0% 11.5% 12.5% 0.062
Mortality 1.6% 1.6% 1.6% 0.757
Bleeding 3.3% 5.5% 7.3% <0.001
Vascular complications 1.0% 1.1% 1.0% 0.511
Cardiac complications 3.0% 3.1% 4.2% <0.001
Stroke 2.9% 3.5% 2.1% <0.001






























































AIRD: autoimmune rheumatic disease; RA: rheumatoid arthritis
Supplementary Table S4. Adjusted odds ratios (OR) of in-hospital adverse events in patients with 
rheumatoid arthritis (RA), stratified by steroid use*
RA-no steroids* RA-steroids*
Outcome OR (95% CI) p-value OR (95% CI) p-value
Any complication 0.96 [0.91, 1.01] 0.099 0.99 (0.89, 1.09) 0.803
Mortality 0.84 [0.74, 0.94] 0.003 0.69 (0.52, 0.90) 0.007
Bleeding 1.03 [0.96, 1.10] 0.433 1.35 (1.18, 1.55) <0.001
Vascular 
complications
0.79 [0.69, 0.91] 0.001 0.72 (0.52, 0.98) 0.047
Cardiac complications 1.02 [0.93, 1.12] 0.696 1.31 (1.11, 1.56) 0.002
Stroke 0.99 [0.91, 1.07] 0.761 0.59 (0.47, 0.73) <0.001
*reference group: patients without autoimmune rheumatic disease or steroid use; CI: Confidence 
interval; RA: rheumatoid arthritis.
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